Advanced Cell Diagnostics Inc., a world leader in the field of in situ nucleic acid detection for life science research and clinical diagnostics, today announced the appointment of Tom Olenic to its executive leadership team as Chief Commercial Officer.

 Mr. Olenic has more than 25 years’ commercial and executive management experience in the biotechnology industry. Prior to joining ACD, Tom was General Manager of the Sequencing Organization and Senior VP of Commercial Operations of the Forensic Organization at IntegenX, Inc., where he implemented an aggressive global commercial strategy that achieved rapid revenue growth. He has also held commercial and senior management roles in companies ranging from startups to public corporations including Bios Corp., PerSeptive Bioscience, Millipore, Molecular Devices (a Danaher Company) and FreeSlate. At Molecular Devices, Tom held successful commercial leadership positions with increasing responsibilities, ending as the General Manager of an organization that grew from $10 million to over $200 million in annual revenue.

 “ACD and its RNAscope technology have already established a great reputation in life science research. I’m so excited to build on the early success and help scale up the commercialization to the next level.” said Mr. Olenic.

 “ACD’s RNAscope has become indispensable for many researchers at the cutting edge to address the challenges of tumour heterogeneity and tumour microenvironment.” said Dr. Yuling Luo, Chief Executive Officer at ACD. “Tom has a proven track record of success in commercialization from early to major markets. He is a perfect fit for ACD to make RNAscope the assay of choice for the mainstream researchers and pathologists in this genomic era,” Dr. Luo continued.

 For further information, please visit www.acdbio.com.